Curis

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Curis reports reduced losses, positive clinical data drive growth prospects

Curis demonstrated improved financial performance, strengthened by successful fundraising and promising clinical data, positioning the company for future growth.
While facing challenges in regulatory processes and balancing expenses, Curis remains focused on innovation and market opportunities to drive value creation.
Investors should monitor Curis' upcoming presentations and regulatory developments closely, as positive outcomes could significantly impact the company's trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2020 Results - Earnings Call Transcript

Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript

Curis Inc.'s (CRIS) CEO James Dentzer on Q3 2019 Results - Earnings Call Transcript

Curis' (CRIS) CEO Jim Dentzer on Q2 2019 Results - Earnings Call Transcript

Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2019 Results - Earnings Call Transcript

Curis, Inc. (CRIS) CEO Jim Dentzer on Q4 2018 Results - Earnings Call Transcript

Thinly traded Curis, Inc. shares weremoving notably higher Monday on roughly 35 times their average volume.

What's Driving The Rally In Microcap Biotech Curis?

Curis Inc. shares made a massive gain to start out the week.

Why Curis Shares Are Booming

Shares of Curis, Inc. rocketed 93% in very active premarket trade Monday.

Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties

News for Curis Stock (CRIS)